Table 3.

FDA Approvals Under the Animal Rule From 2015 to Present

Date	Drug	Purpose
February 2, 2015	Ciprofloxacin	Supplemental NDA approved: new indications for treatment and prophylaxis of plague due to Yersinia pestis in adult and pediatric patients.
March 25, 2015	Anthrasil, Anthrax immune globulin	Treatment for inhalation anthrax
March 30, 2015	Neupogen	Treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident
May 8, 2015	Avelox	Treatment for plague
November 13, 2015	Neulasta (pegfilgrastim)	Treatment of adult and pediatric patients at risk of developing myelosuppression after radiological/nuclear incident
November 23, 2015	BioThrax	Vaccine for use after known or suspected anthrax exposure

NDA = New Drug Application.